View Future GrowthAvecho Biotechnology 과거 순이익 실적과거 기준 점검 0/6Avecho Biotechnology 의 수입은 연평균 -15.2%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 연평균 10.7%의 비율로 증가했습니다. 매출은 연평균 21%의 비율로 감소해 왔습니다.핵심 정보-15.16%순이익 성장률-4.43%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률5.95%매출 성장률-21.03%자기자본이익률-95.48%순이익률-275.64%최근 순이익 업데이트31 Dec 2024최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Jun 29Avecho Biotechnology Limited Continues Recruitment for Phase III Insomnia Program Following Positive Interim AnalysisAvecho Biotechnology Limited has announced it will continue with recruitment for its world-first Phase III insomnia program following a positive interim analysis evaluating its TPM®-enhanced cannabidiol (CBD) capsule. The interim analysis represents a major value-inflection point for the program, reducing clinical development risk and providing a defined pathway toward completion of the pivotal study. The independent Data Monitoring Board (DMB) has completed its review of the unblinded interim analysis data from the pivotal Phase III clinical trial. The DMB is comprised of independent experts in sleep medicine, clinical safety and biostatistics and is the only body with access to unblinded trial data. The DMB has unanimously recommended the trial continue to the full planned enrolment of 519 participants. The recommendation is highly encouraging as it confirms the study has satisfied the pre-specified criteria established in the trial protocol to progress beyond the interim analysis and continue recruitment of a second patient cohort. The interim analysis was conducted on data from 244 participants randomised across three treatment groups receiving nightly doses of either 150mg CBD, 75mg CBD or placebo in a TPM®-enhanced capsule over an eight-week treatment period. Safety data reviewed at the interim analysis further supported the program, with no serious adverse events (SAEs) recorded across the 244 participants. Tolerability is central to the commercial rationale for the product. The Company is currently conducting a pivotal (Phase III), multi-centre, randomised, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of CBD TPM soft-gel capsules in adults for use in the reduction of insomnia severity. The trial is the largest of its kind testing cannabidiol, taking place at multiple sites around Australia. Aided by advice from international sleep and regulatory experts, the trial has been designed to meet the requirements of the Australian Therapeutic Goods Administration ("TGA"), US Food and Drug Agency and the European Medicines Agency. Trial Participants will be randomly assigned to one of three groups to receive nightly doses of either 75mg or 150mg of CBD, or a placebo for eight weeks. Participants will use validated questionnaires and daily sleep diaries over the course of the study to record the duration and quality of their sleep. Further information about the study can be found at ClinicalTrials.gov (Study Identifier: NCT05840822). In 2025, Avecho licensed Australian commercial rights to the CBD TPM capsule to Sandoz under an agreement that included a USD 3 million upfront payment, potential development and commercial milestones of up to USD 16 million and tiered royalties on future sales. The positive interim analysis strengthens Avecho's commercial position and adds momentum to ongoing licensing discussions covering territories outside Australia. The Company believes the interim outcome enhances the attractiveness of the program to potential commercial partners and strengthens the product's positioning against existing sleep medications. Accordingly, progressing additional regional licensing agreements will be a key strategic priority as Avecho seeks to fund continued development while maximising shareholder value. The Company will also now look to engage with the FDA and other international regulatory agencies to determine the path forward for the product in specific geographies.공시 • Apr 25Avecho Biotechnology Limited, Annual General Meeting, May 26, 2026Avecho Biotechnology Limited, Annual General Meeting, May 26, 2026. Location: grant thornton, collins square, tower 5, level 22, 727 collins stree, melbourne, vic 3008 Australia공시 • Oct 23Avecho Biotechnology Limited has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.Avecho Biotechnology Limited has completed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 500,000,000 Price\Range: AUD 0.005 Discount Per Security: AUD 0.0003 Transaction Features: Subsequent Direct Listing공시 • Apr 24Avecho Biotechnology Limited, Annual General Meeting, May 27, 2025Avecho Biotechnology Limited, Annual General Meeting, May 27, 2025. Location: grant thornton offices at collins square, tower 5, level 22, 727 collins street, melbourne Australia공시 • Mar 01Avecho Biotechnology Limited, Annual General Meeting, May 30, 2024Avecho Biotechnology Limited, Annual General Meeting, May 30, 2024.공시 • Nov 23Avecho Biotechnology Limited has completed a Follow-on Equity Offering in the amount of AUD 6.04685 million.Avecho Biotechnology Limited has completed a Follow-on Equity Offering in the amount of AUD 6.04685 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 536,803,333 Price\Range: AUD 0.006 Discount Per Security: AUD 0.00036 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 471,004,997 Price\Range: AUD 0.006 Discount Per Security: AUD 0.00036 Transaction Features: Subsequent Direct Listing공시 • Jan 12Athenex Submits Avecho's Phytonadione to FDA Pre-INDAvecho Biotechnology Limited announced that its TPM®-enhanced Vitamin K (phytonadione) injectable product has been presented to the FDA by Athenex Pharmaceutical Division, LLC in a pre- Investigational New Drug (pre-IND) meeting request. Phytonadione (Vitamin K1) injections are used to treat bleeding or clotting problems caused by Vitamin K deficiency, reactions to certain medications, or other medical conditions that lead tothinning of the blood. It is routinely administered to infants at birth as a prophylactic, providing protection against bleeding, and in 2021 the US had an overall adult and pediatric approximate market size of USD 87 million, with over 4.9 million units sold. Phytonadione is an insoluble oil that requiresformulation with an emulsifying agent in order to dissolve the drug in a formulation suitable for injection. These excipients are typically hydrogenated castor oil (Cremophor EL) or polysorbate, both of which are associated with adverse side effects when given by injection. In lieu of the adverse excipients traditionally used, Athenex has interest in commercialising Avecho's phytonadione formulation, that uses TPM® to dissolve and solubilise the drug. The FDA's feedback to the pre-IND submission will define the amount of development work remaining before a New Drug Application (NDA) for the product could be filed with the FDA for formal review. If the FDA response to the pre-IND submission is generally favorable, and the remaining development work is commercially feasible, the parties will proceed to a license and development agreement to complete the phytonadione product development work for the NDA submission to the US FDA and product commercialisation. The final commercial terms of a subsequent agreement will be determined once FDA feedback is received.매출 및 비용 세부 내역Avecho Biotechnology가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:AVEF.F 매출, 비용 및 순이익 (AUD Millions)날짜매출순이익일반관리비연구개발비31 Dec 241-32230 Sep 241-32230 Jun 240-32131 Mar 240-32131 Dec 230-32130 Sep 231-43130 Jun 231-43131 Mar 231-33131 Dec 221-22130 Sep 221-22130 Jun 221-23131 Mar 221-33131 Dec 211-33130 Sep 211-33130 Jun 210-33131 Mar 210-33031 Dec 200-33030 Sep 200-22030 Jun 200-22031 Mar 202-12031 Dec 19412030 Sep 19412030 Jun 19503031 Mar 193-23031 Dec 181-44030 Jun 181-66131 Mar 181-77131 Dec 171-98130 Jun 171-168131 Mar 171-178131 Dec 162-178230 Sep 162-179230 Jun 163-179231 Mar 162-189231 Dec 152-209230 Sep 152-178230 Jun 153-147331 Mar 152-106331 Dec 142-763양질의 수익: AVEF.F 은(는) 현재 수익성이 없습니다.이익 마진 증가: AVEF.F는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: AVEF.F은 수익성이 없으며 지난 5년 동안 손실이 연평균 15.2% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 AVEF.F의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: AVEF.F은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(-4.8%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: AVEF.F는 현재 수익성이 없으므로 자본 수익률이 음수(-95.48%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/07/30 04:33종가2025/05/02 00:00수익2024/12/31연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Avecho Biotechnology Limited는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관David StantonNomura Securities Co. Ltd.
공시 • Jun 29Avecho Biotechnology Limited Continues Recruitment for Phase III Insomnia Program Following Positive Interim AnalysisAvecho Biotechnology Limited has announced it will continue with recruitment for its world-first Phase III insomnia program following a positive interim analysis evaluating its TPM®-enhanced cannabidiol (CBD) capsule. The interim analysis represents a major value-inflection point for the program, reducing clinical development risk and providing a defined pathway toward completion of the pivotal study. The independent Data Monitoring Board (DMB) has completed its review of the unblinded interim analysis data from the pivotal Phase III clinical trial. The DMB is comprised of independent experts in sleep medicine, clinical safety and biostatistics and is the only body with access to unblinded trial data. The DMB has unanimously recommended the trial continue to the full planned enrolment of 519 participants. The recommendation is highly encouraging as it confirms the study has satisfied the pre-specified criteria established in the trial protocol to progress beyond the interim analysis and continue recruitment of a second patient cohort. The interim analysis was conducted on data from 244 participants randomised across three treatment groups receiving nightly doses of either 150mg CBD, 75mg CBD or placebo in a TPM®-enhanced capsule over an eight-week treatment period. Safety data reviewed at the interim analysis further supported the program, with no serious adverse events (SAEs) recorded across the 244 participants. Tolerability is central to the commercial rationale for the product. The Company is currently conducting a pivotal (Phase III), multi-centre, randomised, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of CBD TPM soft-gel capsules in adults for use in the reduction of insomnia severity. The trial is the largest of its kind testing cannabidiol, taking place at multiple sites around Australia. Aided by advice from international sleep and regulatory experts, the trial has been designed to meet the requirements of the Australian Therapeutic Goods Administration ("TGA"), US Food and Drug Agency and the European Medicines Agency. Trial Participants will be randomly assigned to one of three groups to receive nightly doses of either 75mg or 150mg of CBD, or a placebo for eight weeks. Participants will use validated questionnaires and daily sleep diaries over the course of the study to record the duration and quality of their sleep. Further information about the study can be found at ClinicalTrials.gov (Study Identifier: NCT05840822). In 2025, Avecho licensed Australian commercial rights to the CBD TPM capsule to Sandoz under an agreement that included a USD 3 million upfront payment, potential development and commercial milestones of up to USD 16 million and tiered royalties on future sales. The positive interim analysis strengthens Avecho's commercial position and adds momentum to ongoing licensing discussions covering territories outside Australia. The Company believes the interim outcome enhances the attractiveness of the program to potential commercial partners and strengthens the product's positioning against existing sleep medications. Accordingly, progressing additional regional licensing agreements will be a key strategic priority as Avecho seeks to fund continued development while maximising shareholder value. The Company will also now look to engage with the FDA and other international regulatory agencies to determine the path forward for the product in specific geographies.
공시 • Apr 25Avecho Biotechnology Limited, Annual General Meeting, May 26, 2026Avecho Biotechnology Limited, Annual General Meeting, May 26, 2026. Location: grant thornton, collins square, tower 5, level 22, 727 collins stree, melbourne, vic 3008 Australia
공시 • Oct 23Avecho Biotechnology Limited has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.Avecho Biotechnology Limited has completed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 500,000,000 Price\Range: AUD 0.005 Discount Per Security: AUD 0.0003 Transaction Features: Subsequent Direct Listing
공시 • Apr 24Avecho Biotechnology Limited, Annual General Meeting, May 27, 2025Avecho Biotechnology Limited, Annual General Meeting, May 27, 2025. Location: grant thornton offices at collins square, tower 5, level 22, 727 collins street, melbourne Australia
공시 • Mar 01Avecho Biotechnology Limited, Annual General Meeting, May 30, 2024Avecho Biotechnology Limited, Annual General Meeting, May 30, 2024.
공시 • Nov 23Avecho Biotechnology Limited has completed a Follow-on Equity Offering in the amount of AUD 6.04685 million.Avecho Biotechnology Limited has completed a Follow-on Equity Offering in the amount of AUD 6.04685 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 536,803,333 Price\Range: AUD 0.006 Discount Per Security: AUD 0.00036 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 471,004,997 Price\Range: AUD 0.006 Discount Per Security: AUD 0.00036 Transaction Features: Subsequent Direct Listing
공시 • Jan 12Athenex Submits Avecho's Phytonadione to FDA Pre-INDAvecho Biotechnology Limited announced that its TPM®-enhanced Vitamin K (phytonadione) injectable product has been presented to the FDA by Athenex Pharmaceutical Division, LLC in a pre- Investigational New Drug (pre-IND) meeting request. Phytonadione (Vitamin K1) injections are used to treat bleeding or clotting problems caused by Vitamin K deficiency, reactions to certain medications, or other medical conditions that lead tothinning of the blood. It is routinely administered to infants at birth as a prophylactic, providing protection against bleeding, and in 2021 the US had an overall adult and pediatric approximate market size of USD 87 million, with over 4.9 million units sold. Phytonadione is an insoluble oil that requiresformulation with an emulsifying agent in order to dissolve the drug in a formulation suitable for injection. These excipients are typically hydrogenated castor oil (Cremophor EL) or polysorbate, both of which are associated with adverse side effects when given by injection. In lieu of the adverse excipients traditionally used, Athenex has interest in commercialising Avecho's phytonadione formulation, that uses TPM® to dissolve and solubilise the drug. The FDA's feedback to the pre-IND submission will define the amount of development work remaining before a New Drug Application (NDA) for the product could be filed with the FDA for formal review. If the FDA response to the pre-IND submission is generally favorable, and the remaining development work is commercially feasible, the parties will proceed to a license and development agreement to complete the phytonadione product development work for the NDA submission to the US FDA and product commercialisation. The final commercial terms of a subsequent agreement will be determined once FDA feedback is received.